Table 2

Distribution of gene polymorphisms according to the histology and the genetic background of the lung tumors

PolymorphismTumor histologyaPKRASbPp53cPp53P
ACbACSCCMutantWTMutantWTG→T/C→Anon-G→T/C→A
Genotype
XRCC3-(Thr241Met)
  Thr/Thr24 (49%)8 (44%)15 (42%)13 (59%)18 (41%)23 (44%)23 (49%)10 (50%)13 (41%)
  Thr/Met18 (37%)8 (44%)14 (39%)0.906 (27%)20 (45%)0.3223 (44%)14 (30%)0.247 (35%)16 (50%)0.54
  Met/Met7 (14%)2 (11%)7 (19%)3 (14%)6 (14%)6 (12%)10 (21%)3 (15%)3 (9%)
  Thr/Met and Met/Met25 (51%)10 (56%)21 (58%)0.799 (41%)26 (59%)0.2029 (56%)24 (51%)0.8410 (50%)19 (59%)0.57
Genotype
NBS1-(Glu185Gln)
  Glu/Glu24 (49%)13 (72%)19 (53%)13 (59%)23 (51%)24 (46%)28 (61%)5 (24%)19 (61%)
  Glu/Gln20 (41%)5 (28%)13 (36%)0.438 (36%)17 (38%)0.7620 (38%)18 (39%)0.01810 (48%)10 (32%)0.014 (<0.001d and 0.20e)
  Gln/Gln5 (10%)0 (0%)4 (11%)1 (5%)5 (11%)8 (15%)0 (0%)6 (29%)2 (6%)
  Glu/Gln and Gln/Gln25 (51%)5 (28%)17 (47%)0.239 (41%)22 (49%)0.7928 (54%)18 (39%)0.1616 (76%)12 (39%)0.011 (0.008d and 1.00e)
Genotype
BRCA2-(Asn372His)
  Asn/Asn26 (53%)10 (56%)21 (58%)10 (45%)25 (57%)28 (54%)25 (54%)12 (60%)16 (47%)
  Asn/His19 (39%)5 (28%)11 (31%)0.8010 (45%)14 (32%)0.5520 (8%)14 (30%)0.438 (40%)12 (40%)0.25
  His/His4 (8%)3 (17%)4 (11%)2 (9%)5 (11%)4 (46%)7 (15%)0 (0%)4 (13%)
  Asn/His and His/His23 (47%)8 (44%)15 (42%)0.8912 (55%)19 (43%)0.4424 (46%)21 (46%)1.008 (40%)16 (53%)0.57
  • a Calculated for those patients with available information.

  • b Calculated only in the ACs and bACs histological types for which we had KRAS data available.

  • c Calculated for individuals with p53 mutational status available.

  • d P corresponding to the comparisons between p53-wild type tumors versus tumors with mutations G→T/C→A.

  • e P corresponding to the comparisons between p53-wild type tumors versus non-G→T/C→A mutations.